Artios Pharma Strengthens Leadership Team with Three Key Appointments to Advance DNA Damage Response Pipeline
核心洞察
Artios Pharma appointed three senior executives to strengthen late-stage development capabilities as the company advances its DNA Damage Response pipeline toward commercialization.
Roy W. Ware joins as Chief Manufacturing and Technology Officer, bringing over 20 years of experience in advancing first-in-class oncology programs through FDA approval.
The leadership team will support the advancement of alnodesertib (搜索) into late-stage development and potential U.S. commercialization while executing Phase 2 studies for ART6043.
Artios Pharma Limited (搜索), a clinical-stage biopharmaceutical company pioneering DNA Damage Response (DDR) medicines, announced the appointment of three senior leaders to strengthen its late-stage development capabilities and preparation for commercial readiness. The appointments come as the company rapidly advances alnodesertib (搜索) into late-stage development and potential commercialization in the U.S. while simultaneously executing a Phase 2 study for ART6043.
Key Leadership Appointments
Roy W. Ware, PhD, MBA, joins Artios as Chief Manufacturing and Technology Officer (CMTO), leading Chemistry, Manufacturing and Supply Chain (CMSC) operations for the company's DDR-based therapeutics pipeline. Caryn Barnett has been appointed Vice President of Clinical Operations, and Pablo Lee, MD, MBA, as Vice President of Medical Affairs.
"Roy brings a proven track record of advancing complex, first-in-class oncology programs from early development through approval and into global supply," said Mike Andriole, Chief Executive Officer of Artios. "Combined with Caryn's deep expertise in late-stage clinical operations and NDA submissions, and Pablo's extensive experience building high-performing global medical affairs organizations, these leaders further strengthen an already exceptional team at Artios."
Manufacturing and Technology Leadership
Dr. Ware brings more than two decades of experience spanning CMC strategy, manufacturing, and global supply chain leadership from drug discovery through commercial launch. Most recently, he served as Chief Manufacturing and Technology Officer at Chimerix (acquired by Jazz Pharmaceuticals), where he led Chemistry, Manufacturing and Controls (CMC) and Supply Chain operations and oversaw submissions that supported FDA approvals for Tembexa® (brincidofovir) for smallpox and Modeyso (搜索)® (dordaviprone) for H3 K27M-mutant diffuse midline glioma.
"Artios has firmly established itself as a leader in targeting the DNA Damage Response, advancing an industry-leading pipeline and delivering positive clinical data for its lead program, alnodesertib (搜索), in hard-to-treat solid tumors," said Dr. Ware. "Joining the company at this pivotal stage presents an exciting opportunity to help drive late-stage development, enable potential approval, and ultimately bring a novel treatment option to patients who need it most."
Clinical Operations and Medical Affairs Expertise
Ms. Barnett brings over 30 years of biopharmaceutical industry experience spanning clinical operations, late-stage development, regulatory submissions and inspection readiness. She has led late-phase solid tumor oncology programs through registration and approval, contributing to the successful development and approvals of Cyramza® (ramucirumab), Verzenio® (abemaciclib), Pluvicto® (lutetium 177 vipivotide tetraxetan (搜索)) and Modeyso (搜索)® (dordaviprone).
Dr. Lee is a board-certified internist with more than 25 years of experience spanning medical practice, clinical development and global medical affairs. He has led U.S. and global medical affairs organizations at companies including Chimerix and Verastem Oncology, including the recent launch planning and execution of Modeyso (搜索)® (dordaviprone) in H3 K27M-mutant diffuse midline glioma.
DNA Damage Response Pipeline
Artios' mission is to develop new classes of medicines that harness DNA Damage Response (DDR) pathways, targeting DNA replication stress and synthetic lethality, to deliver meaningful survival benefits for patients with cancer. The company's three potentially first-in-class programs, each with a novel mechanism of action, include ATR inhibitor alnodesertib (搜索), the DNA polymerase theta (Polθ) inhibitor ART6043, and a preclinical portfolio of DDRi-ADC candidates with novel payloads.
These leadership appointments collectively establish an integrated, late-stage drug development capability that aligns manufacturing, clinical execution, and global medical affairs as the company advances its pipeline. "Every day we are reminded that patients with the late-stage cancers our pipeline is designed to address do not have time to wait," said Andriole. "These appointments enhance our ability to deliver potential new medicines to patients as quickly as possible."